Effect of aspirin on cardiovascular events and bleeding in the healthy elderly

New England Journal of Medicine

Volumn 379, Issue 16, 2018, Pages 1509-1518

  McNeil, J J ^a   Wolfe, R ^a   Woods, R L ^a   Tonkin, A M ^a   Donnan, G A ^c   Nelson, M R ^a,d   Reid, C M ^a,e   Lockery, J E ^a,f   Kirpach, B ⁱ   Storey, E ^a   Shah, R C ^l   Williamson, J D ^m   Margolis, K L ^j   Ernst, M E ⁿ   Abhayaratna, W P ^g   Stocks, N ^h   Fitzgerald, S M ^a   Orchard, S G ^a   Trevaks, R E ^a   Beilin, L J ^a   Johnston, C I ^a,b   Ryan, J ^a   Radziszewska, B ^o   Jelinek, M ^b   Malik, M ^p   Eaton, C B ^q   Brauer, D ^k   Cloud, G ^a   Wood, E M ^a   Mahady, S E ^a   Satterfield, S ^r   Grimm, R ⁱ   Murray, A M ^i,j   more..

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e CURTIN UNIVERSITY   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^h UNIVERSITY OF ADELAIDE   (Australia)

ⁱ HENNEPIN HEALTHCARE RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

^k MINNESOTA STATE UNIVERSITY   (United States)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF IOWA   (United States)

^o NATIONAL INSTITUTE ON AGING   (United States)

^p LERNER RESEARCH INSTITUTE   (United States)

^q BROWN UNIVERSITY   (United States)

^r UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; AUSTRALIA; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LENGTH OF STAY; LOW DRUG DOSE; LOWER GASTROINTESTINAL HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; SUDDEN CARDIAC DEATH; UNITED STATES; UPPER GASTROINTESTINAL BLEEDING; BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; INDEPENDENT LIVING; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; TREATMENT FAILURE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ASPIRIN; AUSTRALIA; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; INDEPENDENT LIVING; MALE; PLATELET AGGREGATION INHIBITORS; TREATMENT FAILURE; UNITED STATES;

EID: 85054684581     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1805819     Document Type: Article

References (52)

1. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med 2009; 25: 563-577, vii.
2. Australian Bureau of Statistics. 3303.0 - causes of death, Australia, 2016 (http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3303.02016?OpenDocument).
3. Centers for Disease Control and Prevention. LCWK3 - deaths, percent of total deaths, and death rates for the 15 leading causes of death in selected age groups, by race and Hispanic origin, and sex: United States, 2016 (https://www.cdc.gov/nchs/data/dvs/lcwk/lcwk3-hr-2016.pdf).
4. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2751-3.
5. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006; 30: 74-7.
6. Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res 2014; 12: 147-54.
7. Duffy D, Kelly E, Trang A, Whellan D, Mills G. Aspirin for cardioprotection and strategies to improve patient adherence. Postgrad Med 2014; 126: 18-28.
8. Gu Q, Dillon CF, Eberhardt MS, Wright JD, Burt VL. Preventive aspirin and other antiplatelet medication use among U.S. adults aged ≥40 years: data from the National Health and Nutrition Examination Survey, 2011-2012. Public Health Rep 2015; 130: 643-54.
9. Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke 2005; 36: 1801-7.
10. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
11. Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Report no. 13-05195-EF-1. Rockville, MD: Agency for Healthcare Research and Quality, 2015.
12. Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation 2016; 134: 1579-94.
13. Lei H, Gao Q, Liu S-R, Xu J. The benefit and safety of aspirin for primary prevention of ischemic stroke: a meta-analysis of randomized trials. Front Pharmacol 2016; 7: 440.
14. De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012; 307: 2286-94.
15. Andreotti F, Rocca B, Husted S, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015; 36: 3238-49.
16. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2016; 164: 826-35.
17. Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on longterm antiplatelet treatment after vascular events: a population-based cohort study. Lancet 2017; 390: 490-9.
18. Nelson MR, Liew D, Bertram M, Vos T. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥70. BMJ 2005; 330: 1306.
19. McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. DOI 10.1056/NEJMoa1800722.
20. McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. DOI 10.1056/NEJMoa1803955.
21. Nelson M, Reid C, Beilin L, et al. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging 2003; 20: 897-903.
22. ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 2013; 36: 555-64.
23. Wolfe R, Murray AM, Woods RL, et al. The ASPirin in Reducing Events in the Elderly trial: statistical analysis plan. Int J Stroke 2018; 13: 335-8.
24. Margolis KL, Mahady SE, Nelson MR, et al. Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Contemp Clin Trials Commun 2018; 11: 30-6.
25. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69.
26. Stroke - 1989: recommendations on stroke prevention, diagnosis, and therapy: report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 1989; 20: 1407-31.
27. Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiol ogy: possibilities and pitfalls. Int J Epidemiol 2012; 41: 861-70.
28. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011; 107: 1796-801.
29. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a metaanalysis of randomized trials. Am Heart J 2011; 162: 115-24.e2.
30. Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011; 124: 621-9.
31. Raju NC, Eikelboom JW. The aspirin controversy in primary prevention. Curr Opin Cardiol 2012; 27: 499-507.
32. Xie M, Shan Z, Zhang Y, et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One 2014; 9(10): e90286.
33. Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2016; 164: 804-13.
34. Mora S, Manson JE. Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment. JAMA Intern Med 2016; 176: 1195-204.
35. Raju N, Sobieraj-Teague M, Bosch J, Eikelboom JW. Updated meta-analysis of aspirin in primary prevention of cardiovascular disease. Am J Med 2016; 129(5): e35-e36.
36. Trends in coronary heart disease mortality: age groups and populations. Canberra: Australian Institute of Health and Welfare, May 8, 2014 (https://www.aihw.gov.au/reports/heart-stroke-vascular-diseaSeltrends-in-coronary-heart-diseaSelcontents/summary).
37. Waters AM, Trinh L, Chau T, Bourchier M, Moon L. Latest statistics on cardiovascular disease in Australia. Clin Exp Pharmacol Physiol 2013; 40: 347-56.
38. Weir HK, Anderson RN, Coleman King SM, et al. Heart disease and cancer deaths - trends and projections in the United States, 1969-2020. Prev Chronic Dis 2016; 13: E157.
39. Mensah GA, Wei GS, Sorlie PD, et al. Decline in cardiovascular mortality: possible causes and implications. Circ Res 2017; 120: 366-80.
40. Saito Y, Okada S, Ogawa H, et al. Lowdose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation 2017; 135: 659-70.
41. Belch J, MacCuish A, Campbell I, et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
42. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-41.
43. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-8.
44. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312: 2510-20.
45. Uchiyama S, Ishizuka N, Shimada K, et al. Aspirin for stroke prevention in elderly patients with vascular risk factors: Japanese Primary Prevention Project. Stroke 2016; 47: 1605-11.
46. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
47. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
48. Nelson MR, Doust JA. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies. Med J Aust 2013; 198: 606-10.
49. Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016; 164: 836-45.
50. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315-81.
51. Singh G, Arora G, Mannalithara A, Mithal A, Sehgal A, Triadafilopoulos G. Alarmingly poor adherence to low-dose aspirin: a large population-based study. Eur Heart J 2013; 34: Suppl 1: 2522. abstract.
52. Malayala SV, Raza A. Compliance with USPSTF recommendations on aspirin for prevention of cardiovascular disease in men. Int J Clin Pract 2016; 70: 898-906.